About this policy
Summary of Evidence
Analysis of Evidence
General Information
Associated Information
Sources of Information
Bibliography
Revision History Information
Associated Documents
Attachments
Related Local Coverage Documents
Related National Coverage Documents
Public Versions
Keywords
Local Coverage Determination (LCD)
MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma
L39583
Expand All | Collapse All Email Document Download Add to basket
Contractor Information
Contractor Name Contract Type Contract Number Jurisdiction States
LCD Information
Document Information
LCD ID
L39583
LCD Title
MolDX: Molecular Biomarker Testing for Risk Stratification of Cutaneous Squamous Cell Carcinoma
Proposed LCD in Comment Period
N/A
Source Proposed LCD
DL39583
Original Effective Date
For services performed on or after 08/18/2024
Revision Effective Date
N/A
Revision Ending Date
N/A
Retirement Date
N/A
Notice Period Start Date
07/04/2024
Notice Period End Date
08/17/2024
CPT codes, descriptions, and other data only are copyright 2025 American Medical Association. All Rights Reserved. Fee sch
Coverage indications
Current molecular biomarker tests that risk stratify individuals with cutaneous squamous cell carcinoma (cSCC) are non-covered by this contractor.
Codes in this policy
Code numbers and each code’s status as the policy records it. CPT code descriptions are left out of this page, as are the passages that cite CPT codes; the official document has them.
Backwork has no codes on record for this policy. Check the source.